Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase regulation in chronic kidney disease
A Faivre, R Dissard, W Kuo, T Verissimo… - Nephrology Dialysis …, 2023 - academic.oup.com
Background The roles of hypoxia and hypoxia inducible factor (HIF) during chronic kidney
disease (CKD) are much debated. Interventional studies with HIF-α activation in rodents …
disease (CKD) are much debated. Interventional studies with HIF-α activation in rodents …
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European …
S Stoumpos, K Crowe, P Sarafidis… - Nephrology Dialysis …, 2024 - academic.oup.com
Anaemia is a common complication of chronic kidney disease (CKD) and is associated with
poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis …
poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis …
[HTML][HTML] A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
J Liu, S Li, F Yang, T Li, R Li, Y Waheed… - The Korean Journal …, 2024 - ncbi.nlm.nih.gov
Methods Single-center, retrospective study, 81 PD patients (with erythropoietin
hyporesponsiveness) were divided into the roxadustat group (n= 61) and erythropoiesis …
hyporesponsiveness) were divided into the roxadustat group (n= 61) and erythropoiesis …
Therapeutics of managing reduced red cell mass associated with chronic kidney disease–Is there a case for earlier intervention?
J Elliott - Journal of Veterinary Pharmacology and Therapeutics, 2023 - Wiley Online Library
Reduced red cell mass is a poor prognostic indicator in chronic kidney disease (CKD)
patients. Whilst overt anaemia impacts on the quality of life of patients with CKD, lowered red …
patients. Whilst overt anaemia impacts on the quality of life of patients with CKD, lowered red …
[HTML][HTML] Randomized study on the efficacy of standard versus low roxadustat dose for anemia in patients on peritoneal dialysis
Z Yang, T Ma, X Xu, G Fu, J Zhao, Y Xu, B Yang… - Kidney International …, 2022 - Elsevier
Introduction We aimed to investigate whether a lower starting dose of roxadustat (∼ 1–1.4
mg/kg) converted from erythropoiesis-stimulating agent (ESA) could achieve a comparable …
mg/kg) converted from erythropoiesis-stimulating agent (ESA) could achieve a comparable …
Cardiovascular safety of roxadustat in CKD anemia: a fig leaf named noninferiority
WC Winkelmayer, CP Walther - … Journal of the American Society of …, 2021 - journals.lww.com
Considerable excitement has been building in nephrology. A new paradigm for the
treatment of the anemia associated with advanced CKD has arisen from Nobel Prize …
treatment of the anemia associated with advanced CKD has arisen from Nobel Prize …
A phase 3b, multicenter, open‐label, single‐arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations
S Fishbane, M Vishnepolsky… - Hemodialysis …, 2023 - Wiley Online Library
Introduction Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor
approved in several regions for the treatment of anemia of chronic kidney disease (CKD) …
approved in several regions for the treatment of anemia of chronic kidney disease (CKD) …
低氧诱导因子通路在心肾综合征中的作用及低氧诱导因子稳定剂的应用前景
阿柔娜， 何方方， 孙新， 罗长青 - 临床肾脏病杂志, 2022 - lcszb.com
心肾综合征(cardiorenal syndrome, CRS) 是一种多器官疾病, 是指心脏或肾脏其中之一的急性
或慢性功能障碍引起另一器官的急性或慢性功能障碍, 其病理生理涉及免疫炎症, 氧化损伤 …
或慢性功能障碍引起另一器官的急性或慢性功能障碍, 其病理生理涉及免疫炎症, 氧化损伤 …
[HTML][HTML] Safety and effectiveness of recombinant human erythropoietin coupled with different doses of Roxadustat for treatment of renal anemia in patients on …
S Wei, J Sun, K Xu, Y Li, Y Zhang - American Journal of …, 2023 - ncbi.nlm.nih.gov
Objective: To investigate the safety and efficacy of recombinant human erythropoietin
(rHuEPO) in combination with different doses of Roxadustat in treating renal anemia in …
(rHuEPO) in combination with different doses of Roxadustat in treating renal anemia in …
Anemia renal: tratamientos actuales y moléculas emergentes
M Heras-Benito - Revista Clínica Española, 2023 - Elsevier
La anemia es una complicación frecuente de la enfermedad renal cuya prevalencia
aumenta a medida que progresa la enfermedad, empeora la calidad de vida de pacientes y …
aumenta a medida que progresa la enfermedad, empeora la calidad de vida de pacientes y …